b"MyAMLNGS Cancer PanelsClinical InformationUnderstanding the clonal architecture of AML patients isTest Name internal tandem duplications. Coupling comprehensive 1 MyAML identifies all somatic mutations, large and smallgene coverage with enhanced depth of coverage, long vital for successful treatments. Many different mutations,insertions/deletion, and translocations under NCCN/ELNMyAML - NGS gene panel assayread lengths, and the power of our robust annotation epigenetic aberrations, or downstream abnormalities canguidelines, as well as novel somatic variants that may havesoftware and bioinformatics database, MyAML identifies generate the same clinical treatment plan. However, theseprognostic significance for AML.differences are responsible for the variable responsesAssay Type the underlying somatic mutations that are present as low observed with therapy, which is a major feature in patientsScreening with MyAML allows informed treatment decisionsas 5% allelic frequency. The data and report include single with AML 2 . Therefore, since varied somatic mutations affectto be made once all the relevant mutations are known,Next-Generation Sequencing (NGS) base resolution of the genomic breakpoint and sequences patient outcomes, conventional genotyping is no longer theboth in the prevalent clones, as well as the 'secondary' orCLIA-validated assay of mutations, facilitating optimized treatment plans and most suitable method for screening patients.'tertiary' clones, which could become the new prominenttemporal tracking of minimal residual disease.MyAML is a CLIA-validated assay that identifies clinicallyclones leading to recurrence. Method Description A completed patient consent form must be submitted for actionable, pathogenic, and potentially pathogeniceach sample sent to LabPMM.mutations in 194 genes associated with AML. Using theUsing proprietary design, the coding regions and potential genomic breakpoints within known somatic gene fusions latest version in Next-Generation Sequencing chemistry, are sequenced to an average depth of coverage ofIndications for Testing1000x. By utilizing long read lengths, the assay accuratelyAt initial diagnosis of AMLdetects and characterizes the breakpoints of structuralStratifying risk for AMLvariants and gene fusions, often with single base-pair precision. In addition, these long reads enhance the abilityRecurrence of leukemiaList of Genes on the MyAML Panel Other Genes to identify both the insertion site and DNA content of large ABCC1 ACVR2B ADRBK1 AKAP13 ANKRD24 ARID2 ARID4B ASXL1 ASXL2 ASXL3 Structural Rearrangements BCOR BCORL1 BRINP3 BRPF1 BUB1 CACNA1E CBL CBX5 CBX7 CDC73 CEP164 CPNE3 CSF1R CSTF2T CTCF CYLD DCLK1 DDX1 DDX23 DHX32 DIS3 DNAH9 Inv(16) t(16;16) t(8;21) t(15;17) t(9;11) inv(3) t(3;3) t(6;9) t(9;22)DNMT1 DNMT3B DYRK4 EED EGFR EP300 EPHA2 EPHA3 ETV3 EZH2 FANCCTurnaroundShippingStorage GATA1 GATA2 GFI1 GLI1 HDAC2 HDAC3 HNRNPK HRAS IKZF1 JAK1 JAK2 JAK3Interpretation Specimen RequirementsGenesJMJD1C KDM2B KDM3B KDM6A KDM6B KMT2B KMT2C KRAS MAPK1 METTL3Time Conditions ConditionsCEBPA DNMT3A FLT3 IDH1 IDH2 KIT NPM1MST1R MTA2 MTOR MXRA5 MYB MYC MYLK2 MYO3A NF1 NOTCH1 NOTCH2 NRAS NRK OBSCN PAPD5 PAX5 PDGFRA PDGFRB PDS5B PDSS2 PHF6 PKD1L2 PLRG1 POLR2A PRDM16 PRDM9 PRKCG PRPF3 PRPF40B PRPF8 PTEN PTPN11An interpretive7 to 14 3 mL of peripheral blood inAmbient or Room Temp Other Fusions and Gene Rearrangements PTPN14 PTPRT RAD21 RBBP4 RBMX RPS6KA6 SAP130 SCML2 SETBP1 SETD2 SF1report will bebusiness days Heparin, EDTA or ACD Cool; do notup to 72 hoursABL1 ADGRG7 AFF1 BCR CBFB CREBBP DEK EIF4E2 ELL ETV6 GAS6 GAS7SF3A1 SF3B1 SMC1A SMC3 SMC5 SMG1 SNRNP200 SOS1 SPEN SRRM2 SRSF2 KAT6A KAT6B KMT2A MECOM MKL1 MLLT10 MLLT1 MLLT3 MLLT4 MYH11SRSF6 STAG2 STK32A STK33 STK36 SUDS3 SUMO2 SUPT5H SUZ12 TCF4 TET1issued indicating1 mL of bone marrow infreeze 2-8 C upNSD1 NUP214 NUP98 PICALM PML RARA RBM15 RPN1 RUNX1 RUNX1T1 SEPT5TET2 THRB TP53 TRA2B TRIO TTBK1 TYK2 TYW1 U2AF1 U2AF1L4 U2AF2 UBA3the SNVs, indels, SET TFG TMEM255BWAC WAPAL WEE1 WNK3 WNK4 WT1 ZBTB33 ZBTB7B ZRSR2inversions andHeparin, EDTA or ACD to 7 daystranslocations Cell Pellets in cell cultureidentified media or buffered solutions without fixatives1 g of purified, high qualitygenomic DNAReferences1.Dhner K et al. (2014) Intermediate-risk acute myeloid leukemia therapy: current and future. Hematology Am Soc HematolEduc Program 1,34-43. 2.Estey EH (2014) Acute myeloid leukemia: 2014 update on risk-stratification and management. Am J Hematol 89:1063-1081. 52 LabPMM Services Catalog 2020|53"